You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)獲Boston Immune授予開發獨家選擇授權
阿思達克 02-18 09:15
百濟神州(06160.HK)公布,與美國Boston Immune Technologies and Therapeutics, Inc(BITT)達成一項選擇和授權協定,百濟神州已經獲得BITT專利保護的TNFR2拮抗劑抗體、於亞洲(日本除外)、澳洲及紐西蘭的獨家開發、生產和商業化授權選擇權。

雙方計劃啟動多項1期臨床試驗,以評估BITT的先進TNFR2拮抗劑抗體BITR2101,包括其聯合百濟神州抗PD-1抗體「百澤安」(替雷利珠單抗)的組合用藥研究。

根據協議條款,BITT將獲得共計1,660萬美元的預付款及近期里程碑付款,其中包括百濟神州在概念驗證研究后行使選擇權。此外,在百濟神州行使選擇權后,BITT有資格獲得至多為1.05億美元的開發、註冊及銷售里程碑付款,另加在授權地區的分級產品銷售特許使用費。

連同該項獨家選擇和授權協定,百濟神州同時參與BITT的A輪優先股融資,涉及投資400萬美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account